Clarity Pharmaceuticals (CU6) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones, including progression of two Phase III trials and positive data from Phase II studies in prostate cancer and neuroendocrine tumours.

• Raised $203.6 million in a placement, strengthening the cash position to $277 million post-placement.

• Refocused strategy on high-value, high-probability clinical programs, prioritizing SAR-bisPSMA, SARTATE, and SAR-Bombesin.

• Expanded manufacturing and supply chain agreements to support anticipated commercial rollout.

Financial highlights

• Net loss for the year was $64.3 million, compared to $42.3 million loss in the prior year, driven by increased R&D expenditure.

• Research and development expenses rose by $21.1 million to $66.9 million, reflecting expanded clinical trial activity.

• Cash and financial assets at 30 June 2025 were $84.1 million, with a pro-forma cash balance of $277 million after the July placement.

• No dividends declared or paid.

Outlook and guidance

• Well-funded to support ongoing and future clinical programs through FY2026.

• Focus remains on progressing late-stage clinical trials and preparing for commercialisation in the US oncology market.

• Anticipates further data readouts and regulatory submissions for lead products in the coming year.